For years, physicians have used nasal catheters
to measure esophageal acid levels with pH testing in patients suspected of having acid reflux, or gastroesophageal reflux disease (GERD).
Its lead product, RhinoChill(TM), which was used in the PRINCE study, can be administered quickly and close to the brain using a nasal catheter
that delivers a rapidly evaporating coolant.
But, primarily because the Bravo System was more comfortable than the nasal catheter
, they left the capsule in place and recorded results for an additional 18-24 hours in 83 patients.
Its lead product, RhinoChill(TM), which was used in the PRINCE study, can be administered quickly and directly to the brain by a proprietary portable system that uses a nasal catheter
to deliver a rapid evaporative coolant.
To diagnose GERD, physicians examine the esophagus with an endoscope and, before the Bravo system was commercially introduced by Medtronic last May, typically inserted a nasal catheter
to measure the pH (acidity) level in the esophagus.
The RhinoChill System uses a nasal catheter
to deliver a proprietary inert coolant to the nasal cavity to reduce patient temperature.
The Bravo System offers a convenient test that leads to a more accurate GERD diagnosis without requiring a 24-hour nasal catheter